Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naxitamab (Primary) ; Granulocyte macrophage colony stimulating factor; Irinotecan; Sargramostim; Temozolomide; Temozolomide
Indications Neuroblastoma
Focus Adverse reactions; Therapeutic Use
Acronyms HITS

Most Recent Events

16 Oct 2023 According to a Y-mAbs Therapeutics media release, data from this study were published in the journal Cancers.
16 Oct 2023 Results published in an Y-mAbs Therapeutics Media Release.
16 Oct 2023 According to a Y-mAbs Therapeutics media release, Dr. Jaume Mora is the principal investigator of this study.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight